Kyttaro Therapeutics was incorporated in the US in 2021 to commercialize technologies developed by the founders of Apceth Biopharma GmbH since 2007. The company is headquartered in New York, with research operations in Germany.
Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of mesenchymal stem cells (MSCs) for treatment of diseases with a high, unmet clinical need.
Kyttaro’s expertise and intellectual property are based on 15 years of research and development in Germany and around the world in cutting-edge applications for MSC Alpha-1 Antitrypsin (MSC-AAT), MSC Cytokines (MSC-Cyt) and MSC-Klotho.
Company Details
- Employees
- 4
- Founded
- 2021
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://kyttarotherapeutics.com/
- Keywords
- Philadelphia.
Kyttaro Therapeutics Questions
Kyttaro Therapeutics's website is https://kyttarotherapeutics.com/
Kyttaro Therapeutics's LinkedIn profile is https://www.linkedin.com/company/kyttarotherapeutics
Kyttaro Therapeutics has
4 employees.
View email and phone details for 4
employees at Kyttaro Therapeutics.
Kyttaro Therapeutics's industry is
Biotechnology Research
Kyttaro Therapeutics's top competitors are
Cobiomic Bioscience Sl,
Genesis Biocapital,
Tiaris Biosciences Sl,
Biomixing S.l.,
Persephoni Bio,
Micregen Ltd,
Leucadia Therapeutics,
Komo Biosciences,
Smart Bio Works Llc,
Made Scientific.
Kyttaro Therapeutics's categories are Biotechnology Research
Kyttaro Therapeutics's founding year is 2021
